新型环流左心室辅助装置减少血液创伤:改善血液相容性的意义
本研究在体外循环回路中比较TORVAD与HeartMate II对血液创伤的影响。结果显示TORVAD显著减少血管性血友病因子降解、血小板活化和溶血,提示其血液相容性优于HeartMate II。
要点
- TORVAD体外循环6小时对血管性血友病因子的降解显著低于HeartMate II。
- TORVAD不引起血小板活化,而HeartMate II引起显著活化。
- TORVAD所致溶血极轻微,显著低于HeartMate II。
核心结论
- TORVAD设计具有显著更低的剪切应力和搏动性血流,所致血液创伤显著少于HeartMate II。
研究设计与样本
- 体外循环回路中循环人全血6小时,比较HeartMate II(n=8)与TORVAD(n=6)的血液创伤标志物。
主要发现
- TORVAD高分子量血管性血友病因子多聚体降解为-10%±1%,HeartMate II为-21%±1%(p<0.0001)。
- TORVAD低分子量血管性血友病因子多聚体积累为22%±2%,HeartMate II为45%±2%(p<0.0001)。
- TORVAD血管性血友病因子降解片段积累为7%±1%,HeartMate II为25%±6%(p<0.05)。
- 血小板活化(CD 41/61)TORVAD为645±20 ng/mL,HeartMate II为1,581±150 ng/mL(p<0.001)。
- 血浆游离血红蛋白TORVAD为11±2 mg/dL,HeartMate II为109±10 mg/dL(p<0.0001)。
关键数值与推荐
- 正常人体CD 41/61为593 ng/mL(范围400至800)。
- 正常人体血浆游离血红蛋白<4 mg/dL。
临床怎么用
- TORVAD可能减少左心室辅助装置相关血液创伤,从而改善临床结局并扩大适用人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) cause blood trauma that includes von Willebrand factor degradation, platelet activation, and subclinical hemolysis. Blood trauma contributes to bleeding, thrombosis, and stroke, which cause significant morbidity and mortality. The TORVAD (Windmill Cardiovascular Systems, Inc, Austin, TX) is a first-of-its kind, toroidal-flow LVAD designed to minimize blood trauma. We tested the hypothesis that the TORVAD causes less blood trauma than the HeartMate II (Abbott Laboratories, Pleasanton, CA) LVAD. METHODS: Whole human blood was circulated for 6 hours in ex vivo circulatory loops with a HeartMate II (n = 8; 10,000 rpm, 70 ± 6 mm Hg, 4.0 ± 0.1 L/min) or TORVAD (n = 6; 144 rpm, 72 ± 0.0 mm Hg, 4.3 ± 0.0 L/min). von Willebrand factor degradation was quantified with electrophoresis and immunoblotting. Platelet activation was quantified by cluster of differentiation (CD) 41/61 enzyme-linked immunosorbent assay (ELISA). Hemolysis was quantified by plasma free hemoglobin ELISA. RESULTS: The TORVAD caused significantly less degradation of high-molecular-weight von Willebrand factor multimers (-10% ± 1% vs -21% ± 1%, p < 0.0001), accumulation of low-molecular-weight von Willebrand factor multimers (22% ± 2% vs 45% ± 2%, p < 0.0001), and accumulation of von Willebrand factor degradation fragments (7% ± 1% vs 25% ± 6%, p < 0.05) than the HeartMate II. The TORVAD did not activate platelets, whereas the HeartMate II caused significant platelet activation (CD 41/61: 645 ± 20 ng/mL vs 1,581 ± 150 ng/mL, p < 0.001; normal human CD 41/61, 593 ng/mL; range, 400 to 800 ng/mL). Similarly, the TORVAD caused minimal hemolysis, whereas the HeartMate II caused significant hemolysis (plasma free hemoglobin: 11 ± 2 vs 109 ± 10 mg/dL, p < 0.0001; normal human plasma free hemoglobin <4 mg/dL). CONCLUSIONS: The TORVAD design, with markedly lower shear stress and pulsatile flow, caused significantly less blood trauma than the HeartMate II. LVADs with reduced blood trauma are likely to improve clinical outcomes and expand LVAD therapy into patients with less advanced heart failure.
引用
- Bartoli CR, Hennessy-Strahs S, Gohean J, et al. A Novel Toroidal-Flow Left Ventricular Assist Device Minimizes Blood Trauma: Implications of Improved Ventricular Assist Device Hemocompatibility. Ann Thorac Surg. 2018. PMID: 30586577. doi:10.1016/j.athoracsur.2018.11.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。